Changes in US stocks | BeiGene (ONC.US) rose more than 4% Agency: Innovative drugs are expected to usher in a revaluation

Zhitongcaijing · 06/09 14:09

The Zhitong Finance App learned that on Monday, BeiGene (ONC.US) rose more than 4% to $267.04. According to news, recently, ASCO was officially held. ASCO is the largest and most academically influential conference in the field of oncology in the world. The ASCO report showed that Cinda Biotech's IBI363 (PD-1/IL2α double antibody) showed excellent efficacy in colorectal cancer and IO-treated non-small cell lung cancer. At the same time, Zejing Pharmaceutical's ZG005 treatment data and RC108 (c-Met ADC) of Rongchang Biotech also showed good data. Societe Generale Securities said that China's innovative drugs have the advantage of high efficiency and low cost development. Currently, they already have competitive advantages on popular technology tracks such as ADC, dual antibodies, and cell therapy, and are expected to continue to show competitiveness in the industry. Institutional analysts believe that looking forward to the future, innovative drugs are expected to usher in a revaluation.